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SUMMARY Stevens-Johnson syndrome mostly involves the 
skin and mucous membranes. The diagnosis is made when 
the characteristic rash appears 1 to 3 weeks after exposure 
to a known stimulus and cannot be explained by some other 
diagnosis. A 62-year-old woman was admitted for evaluation 
of toxoallergic dermatitis and collagenosis. Ten days prior to 
admission she was taking a course of azithromycin for upper 
respiratory tract infection. After a few days she was feeling better 
but maculopapular, erythematous rash developed over her palms, 
accompanied by fever and chills as well as reddish discoloration 
around her eyes. Within the next few days the rash progressed 
to the feet. Routine hematologic, biochemical and immunologic 
studies did not confirm the diagnosis of inflammatory rheumatic 
disease. Corticosteroid therapy with methylprednisolone (1 mg/
kg) for the presumed Stevens-Johnson syndrome was started 
and her condition improved in several days; she became afebrile 
and her skin lesions gradually disappeared. There is only one 
report, in a child, documenting the association of Stevens-
Johnson syndrome with azithromycin, as in this patient.
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INTRODUCTION
 In 1922, Stevens and Johnson (1) described 
two boys with febrile illnesses associated with cu-
taneous lesions similar to those of erythema mul-
tiforme (EM); they also had stomatitis and severe 
conjunctivitis that resulted in visual impairment. 
The disease that they described became known 
as Stevens-Johnson syndrome (SJS), generally 
accepted to be a severe form of EM. In 1950, Tho-
mas proposed that SJS be called erythema mul-
tiforme major while the mild cutaneous form de-
scribed by Hebra be called erythema multiforme 
minor (2). Another syndrome, toxic epidermal 
necrolysis (TEN), or Lyell’s syndrome, in which the 
epidermis is damaged over large confluent areas 
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of the skin surface, and the development of bul-
lae, has also been considered to belong to the ery-
thema multiforme category. The estimated preva-
lence of TEN is 0.4 to 1.2 cases per million popu-
lation. It was initially described in 1956 by Lyell 
in four case reports that compared the disease to 
a scald burn (2). Whether these syndromes, ery-
thema multiforme minor, SJS and TEN, represent 
a continuum or distinct etiopathologic entities, has 
not yet been established (3-9). The disagreement 
focuses on whether the three manifestations (EM, 
SJS and TEN) are different diseases or variations 
within the erythema multiforme spectrum (3,7). 
Descriptive classification focuses on two specific 
areas: the percentage of complete epidermal de-
tachment from the dermis and the nature of dis-
crete lesions. 
 The majority of SJS cases are between ages 
20 and 40, and 20% of cases occur in children and 
adolescents (10). The mortality of SJS is reported 
to be 3% to 19% (11). 
 SJS is believed to be a cell-mediated hyper-
sensitivity reaction to distinct immunologic stimuli, 
including infectious agents and drugs (6). The ve-
siculo-bullous process that is characteristic of SJS 
is most commonly due to an inflammatory reaction 
that results in widespread necrosis of keratinoc-
ytes. In contrast to other cell-mediated hypersen-
sitivity reactions, the epidermal lymphocytes in 
SJS are CD8 T cells, which are probably respon-
sible for necrosis of juxtaposed keratinocytes (6). 
The histology of drug-induced SJS adds more 
support to the hypothesis of a cell-mediated in-
flammatory mechanism. The histopathologic ob-
servation of “satellite cell necrosis”, which refers to 
lymphocytes closely associated to pyknotic cells, 
occurs in both drug-induced SJS and acute graft-
versus-host disease, the mechanism of which is 
known to be immunologic and cell-mediated. This 
makes it likely that the pathogenesis of drug-in-
duced SJS also represents a cell-mediated hyper-
sensitivity reaction. 
 SJS mostly involves the skin and mucous 
membranes. Skin lesions are less than 3 cm in 
diameter, less than 20% of body surface area 
are involved, with minimal mucous membrane in-
volvement, typically symmetric, and involving the 
extremities, mostly dorsal and extensor aspects of 
the hands. The lesions may be erythematous pap-
ules, vesicles, bullae, or iris lesions with the ad-
ditional involvement of at least two mucous mem-
branes, and fever. The appearance of the mucosal 
lesion is erythema and edema, which progress to 
erosions and pseudomembrane formation. Pro-
dromal symptoms such as fever, malaise and 
cough are sometimes reported as a feature, and 
they usually occur seven to ten days prior to full-
blown presentation. Mucosal lesions include con-
junctivitis as well as oral and genital ulcers (12-14). 
The most common and serious long-term SJS se-
quels are ocular complications. The conjunctivitis 
causes damage or complete destruction of goblet 
cells of the conjunctiva, which results in instability 
of the precorneal tear film, and corneal drying and 
opacification. The corneal damage can lead to de-
creased visual acuity and even blindness. The in-
cidence of long-term ocular complications of SJS 
has been reported to range from 10% to 27% of 
patients. In addition, hepatitis, nephritis, gastroin-
testinal bleeding, pneumonia, arthritis, arthralgia, 
fever, and myalgia have all been reported (15). 
 The diagnosis is made when the characteris-
tic rash appears 1 to 3 weeks after exposure to a 
known stimulus and cannot be explained by some 
other diagnosis (4). The precipitating factors are 
divided into medications and infectious processes 
(15,16). The treatment in part depends on the sus-
pected precipitating cause. The implicated drugs 
such as sulfa drugs, penicillin, or anticonvulsants, 
especially phenytoin, should be discontinued. The 
most commonly associated infections are her-
pes simplex and Mycoplasma (17), but there are 
case reports of a variety of other infective agents 
(18). There is a substantial body of literature 
documenting the association of SJS with certain 
drugs. Much of this literature consists of case re-
ports; however, there are several case series. The 
drug class most frequently reported to cause SJS 
are sulfonamides, especially long-acting agents. 
There also are reports of SJS recurring with sub-
sequent readministration of a sulfonamide. Sul-
fonamide-induced SJS generally appears one to 
two weeks of drug therapy initiation. Diphenyl-
hydantoin and penicillin and its derivatives have 
also been strongly implicated in SJS. As with the 
sulfonamides, SJS appears 1 to 2 weeks of drug 
therapy initiation (5,15). There is only one report 
documenting the association of SJS with azithro-
mycin (19), as in our case.
CASE REPORT
 In August 2001, a 62-year-old woman was 
referred to Department of Nephrology for evalu-
ation of toxoallergic dermatitis and collagenosis. 
Ten days prior to referral her family physician had 
prescribed a 1-week course of azithromycin (250 
mg per day) for the treatment of upper respiratory 
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tract infection. After the patient had been taking the 
medication for four days, she was feeling better 
but maculopapular, erythematous rash developed 
over her palms accompanied by fever and chills 
as well as reddish discoloration around her eyes. 
Within the next few days, the rash progressed to 
the feet. She stopped taking azythromycin and was 
seen at emergency department of another hospi-
tal where she was treated with antihistaminics for 
contact dermatitis and suspect Reiter syndrome. 
Due to worsening of her condition (fever with large 
confluent skin areas), the patient was transferred 
to our hospital on day 10 of the symptom onset. 
 Her past medical history disclosed polyarthral-
gia within the last ten years, with sporadic swelling 
of peripheral joints diagnosed as chronic cervico-
brachial and lumbosacral syndrome, and bilateral 
carpal tunnel syndrome treated mostly by physical 
therapy and nonsteroidal anti-inflammatory drugs 
(NSAIDs). A year before, she underwent thor-
ough immunologic check-up because of worsen-
ing of polyarthralgia. All laboratory tests including 
antinuclear antibody and rheumatoid factor were 
within the normal range, making the diagnosis of 
inflammatory rheumatic disease and collagenosis 
less likely. Routine culture of her throat swab was 
positive for beta hemolytic Streptoccocus group A 
and she was treated with penicillin. Approximately 
three months prior to admission, she was treated 
with antimicrobial agents for acute bacterial infec-
tion of her lower urinary tract on two occasions. 
The patient’s family history was unremarkable. 
At the time of admission she was not taking any 
medications, except for antihistaminics (Synopen 
i.v., Dimidril 3x1 tbl).
 On admission, physical examination revealed 
a well-developed 62-year-old female. Her vital 
sings were as follows: temperature 37.5 ˚C, pulse 
72 beats per minute, and blood pressure 120/80 
mm Hg. Head examination revealed periorbital 
erythema with bilateral conjunctivitis and oral ul-
cers. On her both hands, predominately palms, 
the epidermis was separating from the dermis 
in sheets (Nikolsky’s sign) pointing to exfoliative 
dermatitis. Maculopapulous rash was present on 
her right knee, and minor circular, erythematous 
lesions were seen on her feet. There were degen-
erative malformations of the peripheral hand joints 
and knees, with reduction of movements in cervi-
cal and lumbosacral spine. Otherwise, her physi-
cal examination was unremarkable.
 Routine hematology and biochemistry stud-
ies on admission produced the following findings: 
elevated ESR (91 mm/h), CRP (62.6 mg/dL) and 
WBC (12300/mm3); hematocrit 36%; hemoglobin 
125g/L; MCV 89; platelets 255/mm3; serum iron as 
low as 7 μmol/L; UIBC 33 μmol/L; serum sodium 
138 mEq/L; potassium 4.6 mEq/L; chloride 105 
mEq/L; calcium 2.51 mEq/L; blood urea nitrogen 
(BUN), creatinine, bilirubin and urates were within 
the normal range; liver enzymes: alkaline phos-
phatase (AP) 158 U/L; serum glutamic oxaloacetic 
transaminase (AST) 30 U/L; serum glutamic pyru-
vic transaminase (ALT) 45 U/L; total serum protein 
82 g/L with electrophoresis: albumin 35.8 g/L, α1 
globulin 3.6 g/L, α2 globulin 11.1 g/L, β globulin 
10.6 g/L, γ globulin 20.8 g/L.
 The urine was clear and amber in color, with 
acidic pH and specific weight of 1.015 g/mL. Mi-
croscopic examination showed 0-1 leukocyte. To-
tal protein excretion in urine was 0.05 g/24 h (daily 
urinary output 0.8 L). Urine cytology revealed 
rare red blood cells, a few granulocytes, and few 
squamous and transitional epithelial cells. Her 
throat swab culture was positive for Staphyloco-
ccus aureus, while sputum microbiology pointed 
to Candida albicans. Antistreptococcal antibody 
titer (ASOT) increased to 320 IU/mL. Coagulation 
study was normal.
 Autoimmune serology for serologic markers re-
vealed negative antinuclear antibody (ANA) test, 
while anti-dsDNA and ENA were not performed. 
The diagnosis of inflammatory rheumatic disease 
could not be confirmed. Anti HIV was negative. 
There was no clinical sign of herpes simplex in-
fection. Skin testing using scratch-patch test with 
azithromycin was not performed. 
 An ophthalmologist confirmed conjunctivitis 
and corneal lesions. Dermatologic examination 
confirmed the diagnosis of SJS. The patient re-
fused to give approval for taking photographs of 
her skin lesions. 
 Corticosteroid therapy with methylprednisolo-
ne for the presumed SJS was initiated at a dose 
of 80 mg i.v. (1 mg/kg), along with topical treat-
ment. Her condition improved in several days, she 
became afebrile, and her skin lesions gradually 
disappeared. Skin lesions were treated sympto-
matically, with analgesics, antipruritics, and local 
care to lips and gums. Crusted skin lesions were 
kept moist.
 The patient was discharged after 17-day hos-
pital stay, to continue with extensive corticosteroid 
therapy at a dose of 60 mg i.v. at home, then after 
14 days with 40 mg oral corticosteroid, slowly ta-
pering the dose. Other treatments included fluco-
nazole 200 mg i.v. for 10 days and 1 600 000 IU of 
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intramuscular penicillin once a month, with regu-
lar medical follow-up. The steroid was withdrawn 
after 3 months. The 4-month control biochemistry 
testing showed normal ESR, CRP and WBC. Con-
trol throat swab culture and sputum analysis were 
sterile. Control ASOT was within the normal range. 
At 6 months, control ophthalmologist examination 
showed no corneal damage. ENA was negative.
DISCUSSION
 The incidence of severe EM, SJS and TEN 
cases that require hospitalization is about 3 to 8 
per million per year (20). Medications have been 
postulated as the most common etiologic factor 
in erythema multiforme and TEN (5,15). Antibiot-
ics are reported to cause at least 30% to 40% of 
cases, with sulfonamides, tetracyclines, amoxicil-
lin, and ampicillin being most commonly implicated. 
NSAIDs and anticonvulsants, especially Tegretol 
and phenobarbital, have also been reported. There 
have also been isolated reports of erythema multi-
forme occurring after some other medications (16). 
 Patients are often given antibiotics for an in-
fection, and it is difficult to determine whether 
the antibiotic or the infection is responsible for 
the disease. Viral upper respiratory infections, 
Mycoplasma pneumoniae, pharyngitis and her-
pes simplex infection are also reported to cause 
erythema multiforme (17). The list of other possi-
ble etiologies is extensive, and includes systemic 
lupus erythematosus, histoplasmosis, pregnancy, 
malignancy, and external-beam radiation. In most 
series, some cases remain idiopathic. Several au-
thors have postulated an immunologic etiology for 
erythema multiforme, although none was able to 
conclusively demonstrate its pathogenesis (21).
Differential diagnosis includes other diseases that 
can result in cutaneous and mucous membrane le-
sions; vesiculo-bullous diseases such as pemphi-
gus vulgaris, erosive lichen planus, and varicella 
zoster may mimic SJS (20). Behcet’s and Reiter’s 
syndromes may have ocular and genital lesions 
that can be confused with those seen in SJS. 
 It is important to recognize and expeditiously 
treat SJS in order to reduce the likelihood of com-
plications, which can be serious. The most fre-
quent are those associated with ocular involve-
ment. Keratitis, uveitis, and perforation of the bulb 
have all been described with resulting permanent 
visual impairment. Skin damage and sloughing 
may occur. This predisposes the patient to sepsis 
as well as fluid and electrolyte imbalance. If there 
is widespread epidermal necrosis, the diagnosis 
should be TEN or Lyell’s syndrome and the treat-
ment should be similar to that administered to burn 
patients (20). Pneumonia may occur in up to 30% 
of patients with SJS; whether this is a complication 
or a primary infection precipitating SJS, is unclear. 
There are rare case reports of hepatic damage, 
renal insufficiency, and hematologic complications 
(21). In a review of mucosal involvement in 34 SJS 
patients, stomatitis was present in 100%, ocular 
involvement in 86%, genital mucosal or urethral 
involvement in 41%, and involvement of anal mu-
cosa in only 3% of patients (22). 
 Guillaume et al. reviewed 87 cases of TEN 
and found that 77% were caused by an adverse 
drug reaction; the remaining cases were thought 
to be idiopathic (5). The offending drugs in this 
study included sulfonamides, anticonvulsants 
and NSAIDs. The prevalence of TEN is higher in 
patients with HIV disease than in other patients 
because of the increased use of sulfonamides for 
opportunistic infections in these patients (23-25). 
Non-medicamentous causes are extremely un-
common and include bacterial and viral infections, 
immunizations, graft-versus-host reactions, and 
malignant tumors. Some cases of TEN have no 
detectable cause. 
 The most commonly prescribed therapy for SJS 
are corticosteroids (26). Because SJS is respon-
sive to corticosteroids, and other immunosuppres-
sive drugs have reported efficacy, it is most likely 
that an immune mechanism is operative in SJS. 
The most preferred hypothesis is that a cell-medi-
ated hypersensitivity reaction is pathogenic in SJS 
(26,27). There are several lines of evidence that 
support this hypothesis. The time of onset of the 
reaction of one to three weeks after acquisition of 
infection or drug administration is very consistent 
with the temporal response of the known cell-me-
diated hypersensitivity reactions such as graft-ver-
sus-host disease and contact dermatitis. There is 
also a predictable recurrence upon re-exposure to 
the drug, or recrudescence of infection in case of 
herpes simplex. In addition, if corticosteroids are 
tapered too rapidly, there is an exacerbation of 
SJS that can be reversed by increasing the corti-
costeroid dose (26). 
 Currently, most authors do not recommend the 
routine use of systemic steroids in the treatment 
of erythema multiforme or toxic epidermal necroly-
sis. There have been no randomized prospective 
trials, however, some authorities still believe that 
a short-term pulse of steroids early in the disease 
course (as in this patient) may be beneficial in se-
lected patients (19,28). 
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 This is the second report of SJS associated 
with azithromycin and the first one in adult patient. 
Azithromycin has a long half-life, which may be 
related to the higher risk of adverse effects (29). 
However, the patient had acute pharygitis, which 
could prompt the development of SJS.
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With spring time begins the right time for Nivea – creme!, Year 1929
(from the collection of Mr. Zlatko Puntijar)
